Related Articles
Early sorafenib induction after transarterial chemoembolization for unresectable hepatocellular carcinoma: Can sorafenib after TACE improve loco‑regional control?
GALNT14 genotype, α‑fetoprotein and therapeutic side effects predict post‑chemotherapy survival in patients with advanced hepatocellular carcinoma
Efficacy and adverse events of transcatheter arterial chemoembolization in combination with sorafenib in the treatment of unresectable hepatocellular carcinoma
A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma
Sorafenib‑based therapy in HER2‑negative advanced breast cancer: Results from a retrospective pooled analysis of randomized controlled trials